Vendor Intelligence Report: Dankang BioHealth

Executive summary

Across 73 Finnrick lab tests, Dankang BioHealth records 45 passes and 28 failures, an overall pass rate of 62%. The catalog is uneven rather than uniformly weak: GHK-Cu is the clearest relative bright spot, retatrutide and tirzepatide are batch-check candidates rather than clean endorsements, and TB-500 sits at the low end. Ratings become less forgiving under stricter purity and fill thresholds.

Dankang’s public identity is newer and thinner than its factory presentation implies. The visible footprint begins with privacy-protected domains in late 2025, while registry work did not verify a matching Shenzhen corporate entity behind the park-level address, patent claims, clean-workshop copy, or Lancet reference.

The operation also does not look isolated. The report maps a same-template storefront cluster across Dankang, Hengan, Changyuan, NuoPeptide, and a YanSen content lead; tracks an IP migration; and shows how a YanSen review page ends up praising Dankang by name. Anti-fraud popups and Telegram imposter warnings acknowledge brand-confusion pressure without giving buyers a strong public way to authenticate staff, payment accounts, batches, or COAs.

The buyer-recourse signal is more serious than ordinary gray-market noise. Reddit exhibits allege non-delivery, stalled tracking, and dispute-cancellation pressure from named sales personas; the contact surface shows number discrepancies and stripped WhatsApp fields. The practical read is product- and transaction-specific: do not generalize one better peptide record across the catalog or place a large, irreversible order without independent controls.

Inside the full report:

• Per-product pass/fail rates, spark-grid trajectories, and methodology-divergence charts for all 8 tested products
• Corporate-identity review of the Shenzhen address, registry searches, facility claims, patent claims, and Lancet citation gap
• Infrastructure map covering the Dankang, Hengan, Changyuan, NuoPeptide, and YanSen storefront cluster
• Contact-number and authentication analysis, including anti-fraud popups, Telegram imposter warnings, and COA-verification gaps
• Reddit complaint exhibits covering alleged non-delivery, dispute-cancellation pressure, and named sales personas
• Payment-rail and regulatory read, including customs-interdiction context and refund-recourse implications

Risk assessment

• Product-specific quality risk in lower-performing peptides — high: Finnrick data flags TB-500 at 33.2%, NAD+ at 39.54%, MOTS-c at 42.78%, tesamorelin at 50.07%, and borderline BPC-157 at 55.53%; GHK-Cu is the relative bright spot.
• Corporate-identity and manufacturer-claim risk — high: No verifiable Dankang BioHealth entity was found in Chinese registry checks; factory, patent, Lancet, purity, and capacity claims lack identifiers or citations.
• Fulfillment and buyer-recourse risk — high: Reddit materials allege $4,506+ in non-delivery / refund losses and a dispute-cancellation pattern naming Iris and Lina; payment recourse appears limited.
• Brand-authenticity and copycat-control risk — medium: Dankang uses two near-identical domains, sits in a same-template storefront cluster, posts anti-fraud warnings, and provides no public official-channel list or signed COA verification chain.
• Customs-interdiction and regulatory risk — medium: Dankang was not named by CBP, but its China-origin direct-shipment model and catalog overlap a March 31, 2026 CBP seizure of unapproved peptide shipments.